<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954990</url>
  </required_header>
  <id_info>
    <org_study_id>18-0103</org_study_id>
    <nct_id>NCT03954990</nct_id>
  </id_info>
  <brief_title>Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity</brief_title>
  <official_title>Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bacterial vaginosis (BV) is the most common cause of vaginal discharge among repro-ductive&#xD;
      aged women. It is been linked to adverse maternal and neonatal outcomes. Our objective is to&#xD;
      evaluate if the use of a single dose of metronidazole in women with BV at time of delivery&#xD;
      reduces infectious morbidities&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are proposing a double-blinded, placebo controlled, randomized trial of 525&#xD;
      pregnant women undergoing induction or admitted in early labor and who are diagnosed with&#xD;
      bacterial vaginosis. On admission to labor and delivery, patient will be counseled about the&#xD;
      study. Patients who agree to be enrolled, will sign informed consent. Following enrollment&#xD;
      patients will be screened for Bacterial vaginosis by doing a speculum exam and testing for&#xD;
      Amsel's criteria. BV +ve patients will be randomized to receive either metronidazole 2 grams&#xD;
      PO once or identically appearing placebo. The PI, study coordinator, or a collaborator will&#xD;
      be responsible for the informed consent.&#xD;
&#xD;
      This will be a double-blinded randomized clinical trial. Neither the patient nor provider&#xD;
      will be aware of treatment assignment. As with any other in-stance in which antibiotics are&#xD;
      administered, there is a chance of an allergic or other adverse reaction. The patient will&#xD;
      receive standard inpatient monitoring during the labor course and in the postpartum period,&#xD;
      and so any immediate adverse reaction would be promptly detected.&#xD;
&#xD;
      Patient will be assessed intrapartum for development of chorioamninoitis. Postpartum patient&#xD;
      will be assessed for infective complications up to 4 weeks. Neonates will be assessed for&#xD;
      morbidities by chart review for 90 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patient with bacterial vaginosis will be randomized to either treatment group to receive 2 g of metronidazole or control group to receive 2 g of placebo. Randomization to either control or treatment group will be done according to a randomization sequence that is computer generated and maintained by investigational drug pharmacy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients, providers, PI, investigators will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Composite outcome of maternal infections</measure>
    <time_frame>Labor to 4 weeks postpartum</time_frame>
    <description>Including Chorioamnionitis, postpartum endometritis, wound infection, pelvic septic thrombosis, pelvic or abdominal abscess</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Chorioamnionitis</measure>
    <time_frame>From beginning of labor process until time of delivery</time_frame>
    <description>Presumptive or confirmed diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Postpartum Endometritis</measure>
    <time_frame>From time of delivery to 4 weeks postpartum</time_frame>
    <description>Postpartum intrauterine infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Surgical Site Infection</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Including superficial or deep incisional surgical site infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Pelvic Septic Thrombosis</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Infection and thrombosis of pelvic vessels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Pelvic abscess</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Detection of pelvic abscess on imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Puerperal fever</measure>
    <time_frame>From beginning of labor process until time of delivery</time_frame>
    <description>Temperature of ≥ 100.4 F at least twice 30 minutes apart or once ≥ 101F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Maternal Death</measure>
    <time_frame>During labor and up to 4 weeks postpartum</time_frame>
    <description>Death of mother while pregnant or within 28 days of pregnancy termination from any cause related to pregnancy or its management.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of additional postpartum procedures</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Additional imaging and invasive procedures to diagnose or treat postpartum infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Postpartum Antibiotics use</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Number of patients requiring antibiotics secondary to postpartum infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ER and unscheduled postpartum clinic visit</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Number of unscheduled clinic visits and ER visits secondary to infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospital stay postpartum</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Number of days patients admitted to the hospital secondary to infections postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse events</measure>
    <time_frame>4 weeks postpartum</time_frame>
    <description>Allergic reactions (anaphylaxis, angioedema, skin rashes including Stevens Johnson and Toxic Epidermal necrolysis), Gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation, ileus, etc)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Confirmed neonatal sepsis</measure>
    <time_frame>7 days of delivery</time_frame>
    <description>Findings indicating positive cultures of blood, cerebrospinal fluid or urine obtained by catheterization or suprapubic aspiration, or cardiovascular collapse, or an unequivocal X-ray confirming infection in a clinically septic neonate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Suspected neonatal sepsis</measure>
    <time_frame>7 days of delivery</time_frame>
    <description>Presence of clinical signs/symptoms (hypothermia, fever, irritability, poor feeding, hypotonia, etc) causing the clinician to perform a sepsis work-up (blood, urine and/or cerebrospinal fluid, or chest X-ray), excludes routine work-up solely for positive maternal Group B Streptococcus (GBS) status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Neonatal morbidities</measure>
    <time_frame>90 days after delivery</time_frame>
    <description>Including Respiratory Distress syndrome(RDS), Necrotizing enterocolitis(NEC), Intraventricular hemorrhage (IVH), Bronchopulmonary Dysplasia (BPD)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Bacterial Vaginoses</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets oral, 4 tablets once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive 4 tablets (2g) of metronidazole oral once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Oral</intervention_name>
    <description>4 tablets (2 g of metronidazole)</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>4 tablets</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women ≤50 years at the time of admission with the ability to give informed con-sent.&#xD;
&#xD;
          -  Admission for induction of labor or early spontaneous labor with cervix ≤3 cm.&#xD;
&#xD;
          -  Diagnosed with bacterial vaginosis at time of admission or in the week prior to&#xD;
             admission if not treated&#xD;
&#xD;
          -  Gestational age ≥ 34 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Spontaneous rupture of membranes&#xD;
&#xD;
          -  Plan for elective cesarean delivery&#xD;
&#xD;
          -  Allergy or contraindications to metronidazole&#xD;
&#xD;
          -  Receipt of metronidazole or clindamycin in the admission for delivery for other&#xD;
             in-dications.&#xD;
&#xD;
          -  Hemodialysis&#xD;
&#xD;
          -  Severe liver dysfunction&#xD;
&#xD;
          -  Diagnosis of chorioamnionitis at the time of admission&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sangeeta Jain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas medical branch, Galveston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sangeeta Jain, MD</last_name>
    <phone>713-305-5309</phone>
    <email>sajain@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicholas Spencer, MD</last_name>
    <phone>281-435-0312</phone>
    <email>nrspence@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sangeeta Jain, MD</last_name>
      <phone>713-305-5309</phone>
      <email>sajain@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nicholas Spencer, MD</last_name>
      <phone>281-435-0312</phone>
      <email>nrspence@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Megan Shepherd, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacterial Vaginoses in pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

